Volume 19, Issue 5 (Suppl- 2021)                   IJRM 2021, 19(5): 209-209 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Vatannejad A. P-42 Circulating level of plasma Complement C1q/tumor necrosis factor-related protein 15 in polycystic ovary syndrome. IJRM 2021; 19 (5) :209-209
URL: http://ijrm.ir/article-1-2926-en.html
Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran , vatannejad@ ut.ac.ir
Abstract:   (316 Views)
Background: Poly-cystic ovarian syndrome (PCOS) is one of the frequent metabolic and endocrine disorder in women population that has a close relation with parameters of metabolic syndrome and obesity. Studies have shown perturbation of adipokines levels in PCOS patients. Complement C1q/tumor necrosis factor-related protein 15 (CTRP15) is a prologue of adiponectin that indicated a close relation with insulin, glucose and lipids metabolism.
Objective: In the present study we sought to evaluate the levels of this adipokines and its relation with cardiometabomic data.
Materials and Methods: This case-control study carried out on 120 PCOS patients and 60 controls. Serum levels of adiponectin and CTRP15 were determined using ELISA technique.
Results: Serum levels of CTRP15 elevated in patients with PCOS compared to controls while adiponectin decreased considerably. In addition, CTRP15 indicated a relation with BMI, insulin resistance and FSH levels.
Conclusion: Elevated levels of CTRP15 could be a compensatory response in patients with PCOS in response to obesity and insulin resistance, however further studies are needed to dissect the possible underlying mechanism.
Full-Text [PDF 280 kb]   (76 Downloads)    
Type of Study: Congress Abstract | Subject: Reproductive Pattology

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb